Pediatric Orthopaedics
Tocilizumab treatment in systemic juvenile idiopathic arthritis
N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802112 children, ages 2-17, suffering from active systemic juvenile idiopathic arthritis (JIA) for longer than 6 months with inadequate responses to non-steroidal anti-inflammatory drugs were included in this trial. In the first 12 week randomized double blind phase, participants were treated every 2 weeks with ether anti–interleukin-6 receptor antibody tocilizumab or with a placebo given intravenously. For the second phase, patients, meeting the predefined criteria for non-response, were offered open-label tocilizumab extension up to 5 years. In the first 12 weeks, patients demonstrated improvement with tocilizumab treatment compared to the control, but had developed adverse events, such as, infection, neutropenia, and increased aminotransferase levels.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
